Developer docs
API playgroundTry for free, no card

Search company profiles

Hilab

Full company profile

uuid00021od

Namestring
Hilab
Legal namestring
Hilab Ltda.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Hilab is a Brazilian health technology company headquartered in Curitiba that builds a cloud-based point-of-care diagnostic platform paired with a portfolio of four proprietary portable devices: Hilab Lens (digital microscopy for complete blood counts in up to 25 minutes), Hilab Flow (multi-methodology device covering immunochromatography, fluorescence, and colorimetry with the largest point-of-care portfolio on the market), Hilab Volt (electrochemistry results in up to 8 minutes), and Hilab Molecular (RT-PCR-analogous molecular biology in up to 1 hour). Together the devices cover approximately 85% of the most requested medical tests, and results are processed via an AI-powered cloud platform and delivered to physicians, managers, patients, and specialists through dedicated portal personas.

The company operates across six primary use-case segments: public health (real-time epidemiological surveillance), occupational health (PCMSO workplace exams), laboratories and hospitals (operational cost reduction), clinics and medical offices (faster consultations), retail pharmacies (turnkey laboratory-in-pharmacy services), and independent distributors. Distribution combines direct enterprise sales, a pharmacy channel network, occupational health providers, and recruited distributors. Customers include Renault, which uses the platform in occupational health programs.

Hilab's business model blends hardware sales (the four devices), per-test usage revenue on the cloud platform, and recurring enterprise/institutional contracts. The company holds four ANVISA device registrations, ISO 13485 and ISO 9001 certifications, and is compliant with RDC 786/2023. It has raised approximately $27.8 million in disclosed equity funding since 2018 across multiple rounds (MONASHEES, Qualcomm Ventures, Endeavor Catalyst, Peninsula, Bossa Invest, Google for Startups, and most recently eB Capital, Rise Ventures, and Positivo Tecnologia in 2023), won three consecutive iF Design Awards including a 2022 Gold, and has peer-reviewed clinical validation published in Nature Scientific Reports. The company is now expanding beyond Brazil, having won the Macau Government innovation and entrepreneurship competition in 2025 to pursue the Chinese market.

Short descriptiontext

Hilab is a Brazilian health technology company that develops a cloud-based, AI-powered point-of-care diagnostic platform with four proprietary portable devices (Lens, Flow, Volt, Molecular), covering ~85% of most requested medical tests and serving hospitals, laboratories, clinics, pharmacies, occupational health programs, and public health systems in Brazil.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCuritiba, Brazil
HQ citystring
Curitiba
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, medical devices, biomedical equipment, clinical diagnostics, health technology
Industry2 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
Product category
Point-of-Care Diagnostic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Point-of-Care Diagnostic Devices
TypeHardware Sales
Description

Hilab sells portable diagnostic devices (Hilab Lens, Flow, Volt, Molecular) to healthcare providers, laboratories, pharmacies, and occupational health programs. Devices are sold as capital equipment or as part of integrated solution packages.

hilab.com.br
2Diagnostic Testing Services (Per-Test)
TypeUsage Based
Description

The company operates a per-test revenue model through its point-of-care platform, processing samples and delivering results. The platform covers 85% of the most requested medical tests, with a complete test portfolio across its multi-device ecosystem.

hilab.com.br
3Enterprise and Institutional Solutions
TypeSubscription Recurring
Description

Hilab sells integrated diagnostic solutions to large laboratories, hospitals, occupational health programs, and public health systems, with the stated goal of expanding negotiations with major laboratory and enterprise clients.

neofeed.com.br
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Hilab Lens
Description

The smallest point-of-care blood count device in the world, made by digital microscopy with results in up to 25 minutes.

hilab.com.br
+3 more records
Core offering1 text field

Hilab develops and manufactures ultra-compact point-of-care diagnostic devices (Hilab Lens, Flow, Volt, Molecular) that function as mini connected laboratories, paired with a cloud-based AI diagnostic platform that processes health data and delivers results in real time. The portfolio covers approximately 85% of the most requested medical examinations and is sold primarily to healthcare providers, laboratories, hospitals, pharmacies, occupational health programs, and public health systems in Brazil.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Hilab Lens delivers CBC results in up to 25 minutes — compared to hours or days for traditional laboratory processing
+4 more records
Product overview1 text field

Hilab develops a cloud-based point-of-care testing platform powered by AI, offering rapid, accessible diagnostic technology. The portfolio consists of four distinct portable diagnostic devices: Hilab Lens (digital microscopy for complete blood counts in 25 minutes), Hilab Flow (multi-methodology device supporting immunochromatography, fluorescence, and colorimetry with the largest portfolio), Hilab Volt (electrochemistry results in 8 minutes), and Hilab Molecular (molecular biology with RT-PCR analogous methodology in 1 hour). Together these devices cover approximately 85% of the most requested medical examinations, serving public health, occupational medicine, laboratories, hospitals, clinics, and pharmacies.

Product and service4 records
1Hilab Lens
CategoryPoint-of-care diagnostic device - hematology / digital microscopy
Description

The smallest point-of-care complete blood count (hemograma) device in the world, using digital microscopy and AI-powered image analysis to deliver results in up to 25 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710047.

2Hilab Flow
CategoryPoint-of-care diagnostic device - multi-methodology immunoassay
Description

Multi-methodology point-of-care diagnostic device supporting immunochromatography, fluorescence, and colorimetry testing, marketed as having the largest point-of-care portfolio in the market. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, and occupational health programs. ANVISA registration 80583710007.

3Hilab Volt
CategoryPoint-of-care diagnostic device - electrochemistry
Description

The smallest electrochemistry point-of-care device on the market, delivering diagnostic results in up to 8 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710019.

4Hilab Molecular
CategoryPoint-of-care diagnostic device - molecular biology
Description

The smallest molecular biology point-of-care device, using methodology analogous to RT-PCR with results delivered in up to 1 hour. Intended for healthcare providers, laboratories, hospitals, clinics, occupational health programs, and public health systems. ANVISA registration 80583710015.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Hilab won the Macau Government's innovation and entrepreneurship competition (June edition) and is seeking expansion into the Chinese market, with Macau's Chief Executive supporting financial and commercial services between China and Portuguese/Spanish-speaking countries. The Macau government plans to invest 18.1 billion patacas in a science and technology research park expected to be completed by 2029.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Wondfo is a Chinese POC diagnostics company with compact immunology and chemistry analyzers targeting global emerging markets, overlapping with Hilab's pharmacy and occupational health channels.

2Abbott (i-STAT / Point-of-Care)
TypeBroad incumbent
Description

Abbott's i-STAT and broader POC diagnostics franchise competes directly with Hilab's portable analyzers in hospitals, urgent care, and occupational health, with far greater global reach and installed base.

TypeBroad incumbent
Description

Roche's cobas Liat and broader POC/central lab portfolio competes with Hilab Flow, Volt, and Molecular across hospital and pharmacy channels globally, with deep clinical evidence and distribution.

TypeBroad incumbent
Description

Cepheid's GeneXpert molecular POC system is the closest direct competitor to Hilab Molecular, particularly for decentralized RT-PCR-style testing in clinics and public health settings.

TypeBroad incumbent
Description

QuidelOrtho's Sofia and Triage POC immunoassay systems overlap directly with Hilab Flow's immunochromatography and fluorescence menu across pharmacy and clinical settings.

TypeBroad incumbent
Description

Siemens' epoc and RAPIDPoint POC blood gas/chemistry analyzers overlap with Hilab Volt and broader hospital POC menus, with significantly larger sales infrastructure.

TypeDirect peer
Description

Nova's StatStrip and Prime Plus compact blood gas/chemistry analyzers are highly comparable to Hilab Volt in form factor and clinical use cases for point-of-care hospital testing.

TypeDirect peer
Description

SD Biosensor's STANDARD F and iChroma immunochromatography/fluorescence POC systems overlap with Hilab Flow, especially across emerging markets and pharmacy/occupational channels.

TypeBroad incumbent
Description

Mindray's broad in-vitro diagnostics and POC portfolio across hematology, chemistry, and immunoassay competes with Hilab's multi-device offering, especially relevant as Hilab eyes China expansion.

TypeDirect peer
Description

EKF's QuikRead and Hemo Control compact POC hematology and chemistry analyzers are highly comparable to Hilab Lens and Volt in miniaturization and decentralized clinical use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hilab

Point-of-Care Diagnostic Devicesfazumhilab.com.br

Hilab is a Brazilian health technology company that develops a cloud-based, AI-powered point-of-care diagnostic platform with four proprietary portable devices (Lens, Flow, Volt, Molecular), covering ~85% of most requested medical tests and serving hospitals, laboratories, clinics, pharmacies, occupational health programs, and public health systems in Brazil.

What Hilab does

Hilab is a Brazilian health technology company headquartered in Curitiba that builds a cloud-based point-of-care diagnostic platform paired with a portfolio of four proprietary portable devices: Hilab Lens (digital microscopy for complete blood counts in up to 25 minutes), Hilab Flow (multi-methodology device covering immunochromatography, fluorescence, and colorimetry with the largest point-of-care portfolio on the market), Hilab Volt (electrochemistry results in up to 8 minutes), and Hilab Molecular (RT-PCR-analogous molecular biology in up to 1 hour). Together the devices cover approximately 85% of the most requested medical tests, and results are processed via an AI-powered cloud platform and delivered to physicians, managers, patients, and specialists through dedicated portal personas.

The company operates across six primary use-case segments: public health (real-time epidemiological surveillance), occupational health (PCMSO workplace exams), laboratories and hospitals (operational cost reduction), clinics and medical offices (faster consultations), retail pharmacies (turnkey laboratory-in-pharmacy services), and independent distributors. Distribution combines direct enterprise sales, a pharmacy channel network, occupational health providers, and recruited distributors. Customers include Renault, which uses the platform in occupational health programs.

Hilab's business model blends hardware sales (the four devices), per-test usage revenue on the cloud platform, and recurring enterprise/institutional contracts. The company holds four ANVISA device registrations, ISO 13485 and ISO 9001 certifications, and is compliant with RDC 786/2023. It has raised approximately $27.8 million in disclosed equity funding since 2018 across multiple rounds (MONASHEES, Qualcomm Ventures, Endeavor Catalyst, Peninsula, Bossa Invest, Google for Startups, and most recently eB Capital, Rise Ventures, and Positivo Tecnologia in 2023), won three consecutive iF Design Awards including a 2022 Gold, and has peer-reviewed clinical validation published in Nature Scientific Reports. The company is now expanding beyond Brazil, having won the Macau Government innovation and entrepreneurship competition in 2025 to pursue the Chinese market.

Hilab firmographics

Firmographics
Name
Hilab
Legal name
Hilab Ltda.
Website
https://fazumhilab.com.br
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Hilab is a Brazilian health technology company that develops a cloud-based, AI-powered point-of-care diagnostic platform with four proprietary portable devices (Lens, Flow, Volt, Molecular), covering ~85% of most requested medical tests and serving hospitals, laboratories, clinics, pharmacies, occupational health programs, and public health systems in Brazil.
Ownership category
akta.pro rank

Hilab industry classification

Industry
Product category
Point-of-Care Diagnostic Devices
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical and Diagnostic Laboratories (6215)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Point-of-care diagnostics
  • Medical devices
  • Biomedical equipment
  • Clinical diagnostics
  • Health technology

Where Hilab is headquartered

Location

Headquarters

HQ city
Curitiba
HQ country
Brazil
HQ region
Latin America

Offices2 records

Markets served

Hilab business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Point-of-Care Diagnostic Devices: Hilab sells portable diagnostic devices (Hilab Lens, Flow, Volt, Molecular) to healthcare providers, laboratories, pharmacies, and occupational health programs. Devices are sold as capital equipment or as part of integrated solution packages.
  2. Diagnostic Testing Services (Per-Test): The company operates a per-test revenue model through its point-of-care platform, processing samples and delivering results. The platform covers 85% of the most requested medical tests, with a complete test portfolio across its multi-device ecosystem.
  3. Enterprise and Institutional Solutions: Hilab sells integrated diagnostic solutions to large laboratories, hospitals, occupational health programs, and public health systems, with the stated goal of expanding negotiations with major laboratory and enterprise clients.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Hilab product offering

Product offering

Core offering

Hilab develops and manufactures ultra-compact point-of-care diagnostic devices (Hilab Lens, Flow, Volt, Molecular) that function as mini connected laboratories, paired with a cloud-based AI diagnostic platform that processes health data and delivers results in real time. The portfolio covers approximately 85% of the most requested medical examinations and is sold primarily to healthcare providers, laboratories, hospitals, pharmacies, occupational health programs, and public health systems in Brazil.

Product overview

Hilab develops a cloud-based point-of-care testing platform powered by AI, offering rapid, accessible diagnostic technology. The portfolio consists of four distinct portable diagnostic devices: Hilab Lens (digital microscopy for complete blood counts in 25 minutes), Hilab Flow (multi-methodology device supporting immunochromatography, fluorescence, and colorimetry with the largest portfolio), Hilab Volt (electrochemistry results in 8 minutes), and Hilab Molecular (molecular biology with RT-PCR analogous methodology in 1 hour). Together these devices cover approximately 85% of the most requested medical examinations, serving public health, occupational medicine, laboratories, hospitals, clinics, and pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

  • Hilab Lens: The smallest point-of-care blood count device in the world, made by digital microscopy with results in up to 25 minutes.
  • Hilab Flow
  • Hilab Volt
  • Hilab Molecular

Products and services

  • Hilab Lens The smallest point-of-care complete blood count (hemograma) device in the world, using digital microscopy and AI-powered image analysis to deliver results in up to 25 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710047.
  • Hilab Flow Multi-methodology point-of-care diagnostic device supporting immunochromatography, fluorescence, and colorimetry testing, marketed as having the largest point-of-care portfolio in the market. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, and occupational health programs. ANVISA registration 80583710007.
  • Hilab Volt The smallest electrochemistry point-of-care device on the market, delivering diagnostic results in up to 8 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710019.
  • Hilab Molecular The smallest molecular biology point-of-care device, using methodology analogous to RT-PCR with results delivered in up to 1 hour. Intended for healthcare providers, laboratories, hospitals, clinics, occupational health programs, and public health systems. ANVISA registration 80583710015.

Quantifiable outcome

  • Hilab Lens delivers CBC results in up to 25 minutes — compared to hours or days for traditional laboratory processing
  • +4 more outcomes

Companies that use Hilab

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles6 records

Hilab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Hilab partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Macau GovernmentminorStrategic or Co-development Partner · 1 June 2024Hilab won the Macau Government's innovation and entrepreneurship competition (June edition) and is seeking expansion into the Chinese market, with Macau's Chief Executive supporting financial and commercial services between China and Portuguese/Spanish-speaking countries. The Macau government plans to invest 18.1 billion patacas in a science and technology research park expected to be completed by 2029.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Hilab competitors and assessment

Company assessment

Emerging players

  • Wondfo: Wondfo is a Chinese POC diagnostics company with compact immunology and chemistry analyzers targeting global emerging markets, overlapping with Hilab's pharmacy and occupational health channels.

Broad incumbents

  • Abbott (i-STAT / Point-of-Care): Abbott's i-STAT and broader POC diagnostics franchise competes directly with Hilab's portable analyzers in hospitals, urgent care, and occupational health, with far greater global reach and installed base.
  • Roche Diagnostics: Roche's cobas Liat and broader POC/central lab portfolio competes with Hilab Flow, Volt, and Molecular across hospital and pharmacy channels globally, with deep clinical evidence and distribution.
  • Cepheid (Danaher): Cepheid's GeneXpert molecular POC system is the closest direct competitor to Hilab Molecular, particularly for decentralized RT-PCR-style testing in clinics and public health settings.
  • QuidelOrtho: QuidelOrtho's Sofia and Triage POC immunoassay systems overlap directly with Hilab Flow's immunochromatography and fluorescence menu across pharmacy and clinical settings.
  • Siemens Healthineers: Siemens' epoc and RAPIDPoint POC blood gas/chemistry analyzers overlap with Hilab Volt and broader hospital POC menus, with significantly larger sales infrastructure.
  • Mindray: Mindray's broad in-vitro diagnostics and POC portfolio across hematology, chemistry, and immunoassay competes with Hilab's multi-device offering, especially relevant as Hilab eyes China expansion.

Direct peers

  • Nova Biomedical: Nova's StatStrip and Prime Plus compact blood gas/chemistry analyzers are highly comparable to Hilab Volt in form factor and clinical use cases for point-of-care hospital testing.
  • SD Biosensor: SD Biosensor's STANDARD F and iChroma immunochromatography/fluorescence POC systems overlap with Hilab Flow, especially across emerging markets and pharmacy/occupational channels.
  • EKF Diagnostics: EKF's QuikRead and Hemo Control compact POC hematology and chemistry analyzers are highly comparable to Hilab Lens and Volt in miniaturization and decentralized clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Hilab social profiles

Digital presence

Hilab compliance and trust

Trust signal

Compliance3 records

Hilab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hilab leadership team

Management profile

Number of profiles

Profiles4 records

Hilab funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hilab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hilab

What does Hilab do?

Hilab develops and manufactures ultra-compact point-of-care diagnostic devices (Hilab Lens, Flow, Volt, Molecular) that function as mini connected laboratories, paired with a cloud-based AI diagnostic platform that processes health data and delivers results in real time. The portfolio covers approximately 85% of the most requested medical examinations and is sold primarily to healthcare providers, laboratories, hospitals, pharmacies, occupational health programs, and public health systems in Brazil.

Is Hilab a public or private company?

Hilab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hilab founded?

Hilab was founded in 2016. It employs 101 to 250 people.

Where is Hilab based?

Hilab is headquartered in Curitiba, Brazil, in the Latin America region.

How does Hilab make money?

Three revenue lines are on record. Point-of-Care Diagnostic Devices are the primary driver. The others are diagnostic Testing Services (Per-Test) and enterprise and Institutional Solutions.

Who are Hilab's main competitors?

Wondfo is listed as an emerging player. Broad incumbents are Abbott (i-STAT / Point-of-Care), Roche Diagnostics, Cepheid (Danaher), QuidelOrtho, Siemens Healthineers and Mindray. Direct peers are Nova Biomedical, SD Biosensor and EKF Diagnostics.

Does Hilab have an API?

No public API is recorded for Hilab.

What industry is Hilab in?

Hilab's product category is Point-of-Care Diagnostic Devices. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACABAM, Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity). Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MacaubusinessMacau expands tech competition to Spain for Portuguese and Brazilian start-upsThe Macau Government announced it will expand its innovation and entrepreneurship competition to include Spanish start-ups, marking the sixth edition after previously limiting participation to companies from Portugal and Brazil. Brazilian biotechnology start-up Hilab won the most recent edition in June, having developed a portable diagnostic device capable of performing 25 types of tests with a few drops of blood and is seeking expansion into the Chinese market. Macau's Chief Executive has prioritised promoting financial and commercial services between China and Spanish-speaking countries, with the government planning to invest 18.1 billion patacas in a science and technology research park expected to be completed by 2029.NatureClinical validation of the Hilab lens for AI supported point of care CBC testing in pediatric oncologyA study conducted at Erastinho Hospital evaluated the analytical performance of the Hilab Lens, a portable point-of-care device for complete blood count testing, against the standard XE-2100 analyzer. The results demonstrated high precision and strong correlation with reference methods, leading to high satisfaction among caregivers in a pediatric oncology setting. These findings suggest the Hilab Lens is a reliable alternative suitable for resource-constrained environments requiring rapid diagnostic capabilities.F6s19 Top Clinical Labs IT Companies · November 2025The article presents a curated list of 19 top Clinical Labs IT companies and startups as of November 2025, highlighting firms such as Hilab, Healiam, and AgilePath. These entities are characterized by their focus on decentralizing healthcare through portable diagnostics, affordable blood tests, and digital platforms for oncology and remote diagnostics.NeofeedHilab capta rodada liderada pela eB Capital e quer ir além das farmáciasHilab secured a new funding round led by eB Capital, with participation from Rise Ventures and Positivo Tecnologia, to expand its portable laboratory services beyond pharmacies into hospitals, clinics, and traditional diagnostic labs. The healthtech plans to leverage this capital to strengthen governance, onboard executive talent, and pursue international partnerships in markets like Indonesia and India.SecSEC FORM DHi Technologies Holding Ltd. filed a Form D with the U.S. Securities and Exchange Commission for an exempt securities offering under Rule 506(b). The company reported a total offering amount of $38,486,598 USD, with $11,547,734 USD already sold to three investors as of November 2022. Bofa Securities Inc. was engaged as a broker or dealer in connection with this transaction.NatureHilab system, a new point-of-care hematology analyzer supported by the Internet of Things and Artificial IntelligenceThe Hilab system, a point-of-care hematology analyzer, was evaluated against the Sysmex XE-2100 using 450 blood samples. It showed strong correlations (r ≥ 0.8) and high accuracy, precision, and flagging capabilities, with no significant difference between venous and capillary samples.Startupill55 Best Brazil Medical Device StartupsA curated list of 55 Brazil-based medical device startups is presented, covering companies from startups to established brands. The selection emphasizes innovation, growth, and societal impact, with examples including Hilab, brain4care, and GlucoGear.LAVCAPeninsula Participações and Endeavor Catalyst Lead US$10m Series B in Brazilian Healthtech Hilab (em português) - LAVCAPeninsula Participações and Endeavor Catalyst led a US$10m Series B in Hilab, a Brazilian portable blood test device maker. The round implies a R$300m post-money valuation, with monashees and Qualcomm Ventures having invested R$14.7m previously. Hilab launched a C19 diagnostic test and a medical information portal.ContxtoHi Technologies is rushing production of coronavirus testHi Technologies, a Brazil-based biotech, announced its coronavirus test is in mass production, with availability at pharmacies in key locations within weeks. The test costs about R$130 (US$25) and uses Nespresso-like machines for serological testing, with results in 25 minutes. The company hopes to lower the price for broader access.